Gene
CA9
CA9 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (80), Actionable biomarkers (1), Trial mentions (18), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CA9. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 8 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 3 of 8,738 | 0.03% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 4 of 8,275 | 0.05% | 13 of 11,460 | 0.11% |
| 2022 | 1 of 8,285 | 0.01% | 13 of 13,598 | 0.10% |
| 2021 | 0 of 8,692 | 0.00% | 19 of 15,045 | 0.13% |
| 2020 | 0 of 7,640 | 0.00% | 14 of 14,459 | 0.10% |
| 2019 | 0 of 7,300 | 0.00% | 4 of 12,159 | 0.03% |
| 2018 | 0 of 6,927 | 0.00% | 7 of 11,854 | 0.06% |
| 2017 | 0 of 6,558 | 0.00% | 19 of 11,595 | 0.16% |
Showing 10 of 37 years.
Assay-provider ledger (80)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | July 31, 2026 |
| LEICA | Reagent supplier | Clinical validationAnalytical validation | 2 | July 31, 2026 |
| Ventana Medical Systems | Unclassified | Clinical validationAnalytical validation | 5 | July 31, 2026 +1 undated |
| Wuhan Kanglu Biotechnology | Reagent supplier | Clinical validation | 1 | July 31, 2026 |
| Nonagen BioScience Corp | Diagnostic provider | Clinical validationAnalytical validation | 10 | February 01, 2026 +1 undated |
Showing 5 of 80 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CA9 overexpression | SUNITINIB | response-associated | renal carcinoma | Cancer Genome Interpreter |
Trial mentions (18)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00908739 | Trial biospecimen (AACT) |
| NCT00203866 | Trial eligibility (AACT) |
| NCT05879471 | Trial eligibility (AACT) |
| NCT00352859 | Trial eligibility (AACT) |
| NCT05706129 | Trial eligibility (AACT) |
Showing 5 of 18 trial mentions.
Target-disease associations (243)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ascending tubular aorta aneurysm | phenotype | Literature (Europe PMC) |
| B-cell non-Hodgkins lymphoma | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 243 associations.
Vendor sourcing (53)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.533G>T (p.R178L) alteration is located in exon 3 (coding exon 3) of the CA9 gene. This alteration results from a G to T substitution at nucleotide posi... | View ClinVar record SCV003530872.2 |
| American College of Radiology | Trial sponsor | Mentioned in trial textTrial free-text mention | Carbonic anhydrase IX | View trial NCT00794339 |
| American College of Radiology Imaging Network | Trial collaborator | Mentioned in trial textTrial free-text mention | Carbonic anhydrase IX | View trial NCT00794339 |
| Arsenal Biosciences (United States) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Any prior systemic RCC therapy within 14 days of time of cell collection (interval of 28 days will be required if the last immediate treatment contained... | View trial NCT06245915 |
| Arsenal Biosciences (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | CA9 | View trial NCT06245915 |
Showing 5 of 53 sourcing records.
Trial-cited literature (229)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Pathophysiological Markers of Acute Respiratory Distress Syndrome Severity Are Correlated With Ventilation-Perfusion Mismatch Measured by Electrical Impedance Tomography. | Critical care medicine | 2025 | 8 |
| Prospective pilot study with [<sup>89</sup>Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE). | European journal of nuclear medicine and molecular imaging | 2025 | 3 |
| [<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. | The Lancet. Oncology | 2024 | 114 |
| Diagnostic efficacy of [<sup>68</sup>Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma. | European journal of nuclear medicine and molecular imaging | 2024 | 27 |
| Value of [<sup>68</sup>Ga]Ga-NYM046 PET/CT, in Comparison with <sup>18</sup>F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024 | 14 |
Showing 5 of 229 papers.
Protein variant mentions (1)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.C37I | 1 | 2014 | PMID 24604591 |
Literature-extracted relations (109)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CISPLATIN | Chemical | associate |
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. | 2018 |
| DOXORUBICIN | Chemical | associate |
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. | 2018 |
| SUNITINIB | Chemical | negative_correlate |
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. | 2014 |
| Acetazolamide | Chemical | associate |
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. | 2013 |
| Melphalan | Chemical | associate |
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. | 2013 |
Showing 5 of 109 relation assertions.
Organizations publishing (202)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 14 | 2007 to 2024 |
| Government of the United States of America | Government | 10 | 2005 to 2021 |
| Radboud University Medical Center | Hospital | 9 | 2010 to 2024 |
| The University of Texas System | Academic | 8 | 2011 to 2018 |
| Dana-Farber Cancer Institute | Other | 7 | 2015 to 2021 |
Showing 5 of 202 organizations.
Where CA9 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
226 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.